Your AI-Trained Oncology Knowledge Connection!
OSAKA, Japan-Induction with irinotecan (Camptosar) and cisplatin (Platinol) followed by thoracic radiation combined with weekly irinotecan in patients with unresectable non–small-cell lung cancer (NSCLC) seems to be a feasible regimen in a cooperative group setting, according to the preliminary results of a phase II study presented in an ASCO abstract.
MADISON, Wis-The first major trial to compare three of the newest chemotherapy regimens for advanced non–small-cell lung cancer (NSCLC) with the most commonly used combination found that all offered similar survival benefits.
GROSSHANSDORF, Germany-Initial efficacy results of a randomized phase III trial of previously untreated small-cell lung cancer (SCLC) show that paclitaxel (Taxol)/etoposide/carboplatin (TEC) and carboplatin/etoposide/vincristine (CEV) are both well tolerated with similar response rates. The findings were presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
KANAGAWA, Japan-According to the results of a randomized, multicenter phase III trial, irinotecan (Camptosar) plus cisplatin (Platinol) was associated with a highly significant improvement in survival, with less myelosuppression, in patients with extensive-disease small-cell lung cancer (SCLC), compared with the standard therapy of etoposide/cisplatin. The findings were presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
NEW ORLEANS-In patients with brain metastases related to non-small-cell lung cancer, adding paclitaxel (Taxol) plus carboplatin (Paraplatin) to standard radiotherapy may increase overall treatment efficacy, French investigators reported at the 36th Annual Meeting of the American Society of Clinical Oncology.
PHILADELPHIA-Phase III preliminary trial results support the continued use and development of concurrent chemoradiation strategies for patients with unresected stage III non–small-cell lung cancer (NSCLC).
NEW ORLEANS-In elderly non-small-cell lung cancer (NSCLC) patients, the combination of gemcitabine (Gem-zar) plus vinorelbine (Navelbine) yields better survival than vinorelbine alone, according to the final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Giuseppe Frasci, MD, of the National Tumor Institute, Naples, Italy, reported the results at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
HERAKLION, Greece-A multicenter randomized phase III study comparing paclitaxel (Taxol)/etoposide/cisplatin (Platinol) (TEP) with standard-therapy etoposide/cisplatin (EP) in patients with small-cell lung cancer (SCLC) was stopped prematurely due to a 13% toxic death rate, according to a report given at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
NEW YORK-A new screening procedure to detect early lung cancer has the potential to dramatically reduce mortality, Claudia Henschke, MD, PhD, chief, Division of Chest Imaging, Weill Medical College of Cornell University, said at a media briefing.
A landmark research trial by the University of Wisconsin Comprehensive Cancer Center showed that chemotherapy offers survival benefits for advanced, non–small-cell lung cancer patients. The study, presented at the 36th annual meeting of the
OSAKASAYAMA, Japan-Irinotecan (Camptosar) plus cisplatin (Platinol) significantly improves survival, compared to vindesine/cisplatin, in patients with metastatic non–small-cell lung cancer (NSCLC), according to an analysis of two studies presented by Masahiro Fukuoka, MD, of Kinki University School of Medicine, Osakasayama, Japan, at a poster session at the American Society of Clinical Oncology (ASCO) annual meeting
PHILADELPHIA-Fit, elderly patients with non–small-cell lung cancer (NSCLC) can handle platinum-based therapy as well as younger patients, according to a secondary analysis of data from Eastern Cooperative Oncology Group (ECOG) study 5592. Corey Langer, MD, of Fox Chase Cancer Center, presented the analysis at the ASCO annual meeting.
WASHINGTON-The seven largest US cigar companies will place health warnings on their products and advertisements as the result of an agreement with the US Federal Trade Commission. The warnings read: “Cigar smoking can cause cancers of the mouth and throat, even if you do not inhale.” “Cigar smoking can cause lung cancer and heart disease.” “Tobacco use increases the risk of infertility, stillbirth, and low birth weight.” “Cigars are not a safe alternative to cigarettes.” “Tobacco smoke increases the risk of lung cancer and heart disease, even in nonsmokers.”
NAPLES, Italy-In elderly non-small-cell lung cancer (NSCLC) patients, gemcitabine (Gemzar) combined with vinorelbine (Navelbine) was associated with significantly better survival in comparison to treatment with vinorelbine alone, Giuseppe Frasci, MD, reported at the 36th ASCO Annual Meeting.
EAST MELBOURNE, Australia-Positron emission tomography (PET) response to radical chemoradiotherapy or radical radiotherapy can be used to separate non–small-cell lung cancer (NSCLC) patients into groups with widely differing survival probabilities, Michael P. MacManus, MD, reported at the 36th ASCO Annual Meeting.
NEW ORLEANS-A study of biologic markers in non-small-cell lung cancer (NSCLC) has identified several that appear to predict disease recurrence. They also offer some insight into the mechanisms by which NSCLC tumors spread.
NEW ORLEANS-Topotecan (Hycamtin) after standard therapy with etoposide/cisplatin (Platinol) improved progression-free survival but failed to improve overall survival in extensive-disease small-cell lung cancer (SCLC) when compared to observation, according to a randomized phase III trial presented at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
NEW ORLEANS-The addition of paclitaxel (Taxol) to a regimen of etoposide and carboplatin (Paraplatin) led to a modest improvement in response rate and a trend toward improved survival in patients with small-cell lung cancer (SCLC), investigators from Response Oncology Inc., Memphis, Tennessee, reported at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
OSAKA, Japan-Docetaxel (Taxotere) plus irinotecan (Camptosar) seems to have activity comparable to docetaxel plus cisplatin (Platinol) in advanced non–small-cell lung cancer (NSCLC), according to the results of a randomized phase II study reported at ASCO.
At the meeting in July 1999, symposium faculty also led sessions that answered questions from the participants. New applications for the management of non–small-cell lung (NSCLC) cancer provide the focus for these discussions, which
At the meeting in July 1999, symposium faculty also led sessions that answered questions from the participants. New applications for the management of small-cell lung cancer (SCLC) provide the focus for these discussions, which followed
Irinotecan has appeared to have significant activity against previously treated and untreated small-cell lung cancer (SCLC). The major toxicities of irinotecan are neutropenia and diarrhea, although there is interpatient
A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung
This multicenter study enrolled 73 patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC). The study design was based on the hypothesis that the non-overlapping toxicities of a 3-drug
New cases of lung cancer will be diagnosed in an estimated 164,100 Americans in 2000, and approximately 25% or 41,000 of those cases will be small-cell lung cancer (SCLC). Despite initial sensitivity to chemotherapy, only 10%
